ponalrestat has been researched along with Asymmetric Diabetic Proximal Motor Neuropathy in 23 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ponalrestat was clinically well tolerated and had no significant effect on glycaemic control." | 2.67 | A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. ( Ellis, SH; Hardman, M; Honigsberger, L; Krentz, AJ; Nattrass, M, 1992) |
| "Ponalrestat treatment completely prevented the characteristic nerve conduction slowing and structural abnormalities of the node of Ranvier for 4 mo despite only partial preservation of axonal integrity." | 1.28 | Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat. ( Chakrabarti, S; Greene, DA; Prashar, A; Sima, AA; Zhang, WX, 1990) |
| "Galactose feeding was associated with a 21." | 1.28 | Coexistence of nerve conduction deficit with increased Na(+)-K(+)-ATPase activity in galactose-fed mice. Implications for polyol pathway and diabetic neuropathy. ( Biswas, S; Calcutt, NA; Tomlinson, DR, 1990) |
| "Myo-inositol treatment did not affect nerve levels." | 1.28 | The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats. ( Cameron, NE; Cotter, MA; Robertson, S, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (26.09) | 18.7374 |
| 1990's | 17 (73.91) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Florkowski, CM | 2 |
| Kamijo, M | 2 |
| Cherian, PV | 1 |
| Sima, AA | 3 |
| Valensi, P | 1 |
| Attali, JR | 1 |
| Gagant, S | 1 |
| Krans, HM | 1 |
| Boland, OM | 1 |
| Blackwell, CC | 1 |
| Clarke, BF | 1 |
| Ewing, DJ | 1 |
| Mizisin, AP | 1 |
| Powell, HC | 1 |
| Faes, TJ | 1 |
| Yff, GA | 1 |
| DeWeerdt, O | 1 |
| Lanting, P | 1 |
| Heimans, JJ | 1 |
| Bertelsmann, FW | 1 |
| Pfeifer, MA | 1 |
| Schumer, MP | 1 |
| Gelber, DA | 1 |
| Yasuda, H | 1 |
| Sonobe, M | 1 |
| Hisanaga, T | 1 |
| Kawabata, T | 1 |
| Maeda, K | 1 |
| Kikkawa, R | 1 |
| Shigeta, Y | 1 |
| Cameron, NE | 2 |
| Cotter, MA | 2 |
| Krentz, AJ | 1 |
| Honigsberger, L | 1 |
| Ellis, SH | 1 |
| Hardman, M | 1 |
| Nattrass, M | 1 |
| Ziegler, D | 1 |
| Mayer, P | 1 |
| Rathmann, W | 1 |
| Gries, FA | 1 |
| Yagihashi, S | 1 |
| Rowe, BR | 1 |
| Nightingale, S | 1 |
| Harvey, TC | 1 |
| Barnett, AH | 1 |
| Zhang, WX | 2 |
| Chakrabarti, S | 2 |
| Greene, DA | 2 |
| Prashar, A | 1 |
| Calcutt, NA | 1 |
| Tomlinson, DR | 1 |
| Biswas, S | 1 |
| Dahlin, LB | 1 |
| Archer, DR | 1 |
| McLean, WG | 1 |
| Robertson, S | 1 |
| Umeda, F | 1 |
| Noda, K | 1 |
| Hashimoto, T | 1 |
| Yamashita, T | 1 |
| Nawata, H | 1 |
| Sundkvist, G | 1 |
| Lilja, B | 1 |
| Rosén, I | 1 |
| Agardh, CD | 1 |
| Hotta, N | 1 |
| Sakamoto, N | 1 |
| Kador, PF | 1 |
| Kinoshita, JH | 1 |
| Sharpless, NE | 1 |
4 reviews available for ponalrestat and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
Recent clinical experience with aldose reductase inhibitors.
Topics: Aldehyde Reductase; Biopsy; Diabetic Neuropathies; Double-Blind Method; Humans; Imidazoles; Imidazol | 1993 |
Aldose reductase inhibitors: the end of an era or the need for different trial designs?
Topics: Aldehyde Reductase; Autonomic Nervous System; Diabetic Neuropathies; Enzyme Inhibitors; Humans; Imid | 1997 |
[Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
Topics: Aldehyde Reductase; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies | 1987 |
Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Topics: Aldehyde Reductase; Animals; Binding Sites; Blood Glucose; Cataract; Chemical Phenomena; Chemistry; | 1985 |
10 trials available for ponalrestat and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy.
Topics: Aldehyde Reductase; Diabetes Complications; Diabetic Neuropathies; Double-Blind Method; Humans; Phth | 1993 |
Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy.
Topics: Aldehyde Reductase; Analysis of Variance; Blood Glucose; Blood Pressure; Diabetic Neuropathies; Doub | 1993 |
Recent clinical experience with aldose reductase inhibitors.
Topics: Aldehyde Reductase; Biopsy; Diabetic Neuropathies; Double-Blind Method; Humans; Imidazoles; Imidazol | 1993 |
Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus.
Topics: Aldehyde Reductase; Analysis of Variance; Autonomic Nervous System; Blood Pressure; Diabetes Mellitu | 1993 |
Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor.
Topics: Aldehyde Reductase; Autonomic Nervous System Diseases; Diabetic Neuropathies; Double-Blind Method; F | 1993 |
Aldose reductase inhibitors: the end of an era or the need for different trial designs?
Topics: Aldehyde Reductase; Autonomic Nervous System; Diabetic Neuropathies; Enzyme Inhibitors; Humans; Imid | 1997 |
A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy.
Topics: Action Potentials; Adult; Aldehyde Reductase; Analysis of Variance; Blood Pressure; Diabetic Neuropa | 1992 |
One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dou | 1991 |
Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy.
Topics: Aldehyde Reductase; Diabetic Neuropathies; Humans; Median Nerve; Middle Aged; Neurons, Afferent; Pht | 1991 |
Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function.
Topics: Adult; Aldehyde Reductase; Autonomic Nervous System Diseases; Clinical Trials as Topic; Diabetic Neu | 1987 |
11 other studies available for ponalrestat and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W-rat.
Topics: Aldehyde Reductase; Animals; Atrophy; Axons; Diabetes Mellitus, Type 1; Diabetic Neuropathies; Diabe | 1993 |
Schwann cell injury is attenuated by aldose reductase inhibition in galactose intoxication.
Topics: Aldehyde Reductase; Animals; Body Water; Diabetic Neuropathies; Electrolytes; Female; Galactose; Pht | 1993 |
A combination of the aldose reductase inhibitor, statil, and the prostaglandin E1 analogue, OP1206.alpha CD, completely improves sciatic motor nerve conduction velocity in streptozocin-induced chronically diabetic rats.
Topics: Aldehyde Reductase; Alprostadil; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Hy | 1992 |
Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetic Neuropathies; Fructose; Hypoglycem | 1992 |
[Diabetes mellitus and its complications in Japan. Polyol pathway and diabetic neuropathy: selective preventive effect of aldose reductase inhibitor on the experimental diabetic neuropathy].
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Peripheral Nerv | 1991 |
Diabetic autonomic neuropathy in BB rats and effect of ARI treatment on heart-rate variability and vagus nerve structure.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetic Neuropathies; Glycated Hemoglobin; | 1990 |
Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
Topics: Aldehyde Reductase; Animals; Axons; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropa | 1990 |
Coexistence of nerve conduction deficit with increased Na(+)-K(+)-ATPase activity in galactose-fed mice. Implications for polyol pathway and diabetic neuropathy.
Topics: Aldehyde Reductase; Animals; Diabetic Neuropathies; Diet; Female; Galactose; Mice; Mice, Inbred Stra | 1990 |
Treatment with an aldose reductase inhibitor can reduce the susceptibility of fast axonal transport following nerve compression in the streptozotocin-diabetic rat.
Topics: Aldehyde Reductase; Animals; Axonal Transport; Diabetes Mellitus, Experimental; Diabetic Neuropathie | 1987 |
The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Inositol; Kinet | 1989 |
Effect of aldose reductase inhibitor (Ponalrestat) on erythrocyte Na,K-ATPase activity in non-insulin-dependent diabetic patients with polyneuropathy.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Erythrocyte Membrane; Female; | 1989 |